Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rapid Identification of Pathogens

Rapid Identification of Pathogens

MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of Complete Blood Count Results Between K3-EDTA- and MgSO<sub>4</sub>-Anticoagulated Samples Using a DxH800 Analyzer.

Journal of clinical medicine·2026

Same author

Genomic characterization of aggressiveness in pituitary neuroendocrine tumors (PitNETs).

Neuro-oncology·2026

Same author

Between presence and influence: National survey stresses need to strengthen the involvement of paramedical professionals in ethical meetings.

Intensive & critical care nursing·2026

Same author

Adrenocortical carcinoma: From genomics to patients.

Annales d'endocrinologie·2026

Same author

Nationwide implementation of exclusion non-invasive prenatal diagnosis for single-gene disorders: Nine-year activity and performance analysis from the French public network.

Annales d'endocrinologie·2026

Same author

Deep learning-based pulmonary nodule risk assessment outperforms established malignancy risk scores in lung cancer screening.

Radiology advances·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

Stratification of COVID-19 Severity Using SeptiCyte RAPID, a Novel Host Immune Response Test.

Victor Gravrand¹, François Mellot², Felix Ackermann³

¹Biology Department, Foch Hospital, 92150 Suresnes, France.

|February 28, 2023

Summary

The SeptiCyte RAPID gene expression assay effectively identifies severe COVID-19 cases, similar to viral sepsis. It accurately predicts ICU admission and lung injury extent, outperforming other biomarkers.

Keywords:

COVID-19 gene expression severity viral sepsis

More Related Videos

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Experiment Videos

Last Updated: Jun 19, 2026

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System

Published on: April 6, 2021

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Area of Science:

Molecular Diagnostics
Infectious Disease Research
Critical Care Medicine

Background:

Severe COVID-19 shares characteristics with viral sepsis due to immune dysregulation.
Accurate early identification of severe COVID-19 is crucial for timely intervention.

Purpose of the Study:

To evaluate the SeptiCyte RAPID gene expression assay for identifying severe COVID-19.
To assess its utility in predicting ICU admission and lung injury severity.

Main Methods:

SeptiCyte RAPID assay measuring PLA2G7 and PLAC8 gene expression in 94 SARS-CoV-2 patients.
Analysis of SeptiScore in relation to disease severity, ICU admission, and lung injury (CT scans).
Comparison with other biomarkers (e.g., CRP) and ROC curve analysis.

Main Results:

SeptiScore correlated positively with COVID-19 severity and ICU admission (AUC=0.81).
SeptiScore predicted significant lung injury (≥50%) with high accuracy (AUC=0.86).
The assay demonstrated superior performance compared to individual biomarkers or combinations for differentiating severe from mild/moderate COVID-19.

Conclusions:

SeptiCyte RAPID is a valuable tool for identifying severe COVID-19 in the emergency department and during patient follow-up.
Its performance is unaffected by anti-inflammatory treatments, unlike CRP.
The assay aids in assessing disease severity and guiding critical care decisions.